Emergent BioSolutions Inc. (0IGA.L)
USD 8.5
(-3.22%)
USD 8.5
(-3.22%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.18 Billion USD | -33.53% |
| 2022 | 1.78 Billion USD | 33.1% |
| 2021 | 1.34 Billion USD | -6.7% |
| 2020 | 1.43 Billion USD | 15.75% |
| 2019 | 1.24 Billion USD | 1.83% |
| 2018 | 1.21 Billion USD | 671.88% |
| 2017 | 157.86 Million USD | -57.78% |
| 2016 | 373.9 Million USD | -2.52% |
| 2015 | 383.57 Million USD | -2.16% |
| 2014 | 392.06 Million USD | 185.21% |
| 2013 | 137.46 Million USD | 12.58% |
| 2012 | 122.1 Million USD | -6.17% |
| 2011 | 130.13 Million USD | 2.67% |
| 2010 | 126.75 Million USD | 25.66% |
| 2009 | 100.87 Million USD | 10.32% |
| 2008 | 91.43 Million USD | -10.66% |
| 2007 | 102.34 Million USD | 2.57% |
| 2006 | 99.78 Million USD | 145.8% |
| 2005 | 40.59 Million USD | -11.95% |
| 2004 | 46.1 Million USD | 0.0% |
| 2002 | 18.63 Million USD | -67.71% |
| 2001 | 57.71 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 1.12 Billion USD | -1.1% |
| 2024 Q1 | 1.13 Billion USD | -3.87% |
| 2023 Q2 | 1.22 Billion USD | -30.03% |
| 2023 Q4 | 1.18 Billion USD | -0.86% |
| 2023 FY | 1.18 Billion USD | -33.53% |
| 2023 Q1 | 1.74 Billion USD | -2.04% |
| 2023 Q3 | 1.19 Billion USD | -2.18% |
| 2022 FY | 1.78 Billion USD | 33.1% |
| 2022 Q4 | 1.78 Billion USD | 22.23% |
| 2022 Q2 | 1.22 Billion USD | 1.42% |
| 2022 Q3 | 1.45 Billion USD | 19.39% |
| 2022 Q1 | 1.2 Billion USD | -10.07% |
| 2021 FY | 1.34 Billion USD | -6.7% |
| 2021 Q1 | 1.37 Billion USD | -4.1% |
| 2021 Q2 | 1.37 Billion USD | -0.42% |
| 2021 Q3 | 1.34 Billion USD | -1.95% |
| 2021 Q4 | 1.34 Billion USD | -0.36% |
| 2020 Q1 | 1.2 Billion USD | -2.97% |
| 2020 FY | 1.43 Billion USD | 15.75% |
| 2020 Q4 | 1.43 Billion USD | 5.23% |
| 2020 Q3 | 1.36 Billion USD | 7.69% |
| 2020 Q2 | 1.26 Billion USD | 5.27% |
| 2019 Q3 | 1.29 Billion USD | -2.52% |
| 2019 Q4 | 1.24 Billion USD | -4.47% |
| 2019 Q2 | 1.33 Billion USD | 14.27% |
| 2019 FY | 1.24 Billion USD | 1.83% |
| 2019 Q1 | 1.16 Billion USD | -4.31% |
| 2018 Q2 | 200.54 Million USD | 7.14% |
| 2018 Q1 | 187.18 Million USD | 18.58% |
| 2018 FY | 1.21 Billion USD | 671.88% |
| 2018 Q3 | 206.97 Million USD | 3.21% |
| 2018 Q4 | 1.21 Billion USD | 488.72% |
| 2017 FY | 157.86 Million USD | -57.78% |
| 2017 Q4 | 157.86 Million USD | -56.21% |
| 2017 Q3 | 360.49 Million USD | 3.03% |
| 2017 Q2 | 349.88 Million USD | 2.54% |
| 2017 Q1 | 341.22 Million USD | -8.74% |
| 2016 Q4 | 373.9 Million USD | -2.73% |
| 2016 FY | 373.9 Million USD | -2.52% |
| 2016 Q1 | 368.91 Million USD | -3.82% |
| 2016 Q2 | 383.79 Million USD | 4.03% |
| 2016 Q3 | 384.4 Million USD | 0.16% |
| 2015 Q3 | 371.23 Million USD | -2.58% |
| 2015 Q1 | 379.96 Million USD | -3.08% |
| 2015 Q4 | 383.57 Million USD | 3.32% |
| 2015 FY | 383.57 Million USD | -2.16% |
| 2015 Q2 | 381.07 Million USD | 0.29% |
| 2014 Q2 | 349.48 Million USD | 1.08% |
| 2014 Q1 | 345.75 Million USD | 151.52% |
| 2014 FY | 392.06 Million USD | 185.21% |
| 2014 Q4 | 392.06 Million USD | 10.08% |
| 2014 Q3 | 356.15 Million USD | 1.91% |
| 2013 Q4 | 137.46 Million USD | 6.89% |
| 2013 Q1 | 102.58 Million USD | -15.99% |
| 2013 Q2 | 106.53 Million USD | 3.85% |
| 2013 FY | 137.46 Million USD | 12.58% |
| 2013 Q3 | 128.6 Million USD | 20.72% |
| 2012 FY | 122.1 Million USD | -6.17% |
| 2012 Q3 | 111.61 Million USD | 6.69% |
| 2012 Q2 | 104.61 Million USD | 1.97% |
| 2012 Q1 | 102.59 Million USD | -21.17% |
| 2012 Q4 | 122.1 Million USD | 9.4% |
| 2011 FY | 130.13 Million USD | 2.67% |
| 2011 Q4 | 130.13 Million USD | 1.31% |
| 2011 Q3 | 128.45 Million USD | 13.93% |
| 2011 Q2 | 112.75 Million USD | 0.36% |
| 2011 Q1 | 112.35 Million USD | -11.36% |
| 2010 Q4 | 126.75 Million USD | 45.29% |
| 2010 Q1 | 93.67 Million USD | -7.14% |
| 2010 Q2 | 83.7 Million USD | -10.64% |
| 2010 Q3 | 87.24 Million USD | 4.23% |
| 2010 FY | 126.75 Million USD | 25.66% |
| 2009 FY | 100.87 Million USD | 10.32% |
| 2009 Q4 | 100.87 Million USD | 27.01% |
| 2009 Q3 | 79.42 Million USD | -17.26% |
| 2009 Q2 | 95.98 Million USD | 5.47% |
| 2009 Q1 | 91 Million USD | -0.48% |
| 2008 Q2 | 96.8 Million USD | 1.85% |
| 2008 Q4 | 91.43 Million USD | -3.31% |
| 2008 Q1 | 95.04 Million USD | -7.14% |
| 2008 FY | 91.43 Million USD | -10.66% |
| 2008 Q3 | 94.56 Million USD | -2.31% |
| 2007 Q3 | 83.25 Million USD | 24.31% |
| 2007 Q2 | 66.97 Million USD | 1.68% |
| 2007 Q4 | 102.34 Million USD | 22.93% |
| 2007 Q1 | 65.87 Million USD | -33.98% |
| 2007 FY | 102.34 Million USD | 2.57% |
| 2006 Q4 | 99.78 Million USD | 34.71% |
| 2006 FY | 99.78 Million USD | 145.8% |
| 2006 Q3 | 74.07 Million USD | 0.0% |
| 2005 Q4 | 40.59 Million USD | 0.0% |
| 2005 FY | 40.59 Million USD | -11.95% |
| 2004 FY | 46.1 Million USD | 0.0% |
| 2004 Q4 | 46.1 Million USD | 0.0% |
| 2002 FY | 18.63 Million USD | -67.71% |
| 2001 Q4 | 1.34 Billion USD | 0.0% |
| 2001 FY | 57.71 Million USD | 0.0% |
| 2000 Q4 | 1.78 Billion USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Editas Medicine, Inc. | 150.05 Million USD | -690.105% |
| Dynavax Technologies Corporation | 375.02 Million USD | -216.14% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | -143.219% |
| Perrigo Company plc | 6.04 Billion USD | 80.375% |
| Illumina, Inc. | 4.36 Billion USD | 72.845% |
| Thermo Fisher Scientific Inc. | 51.88 Billion USD | 97.715% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | -505.708% |
| Walgreens Boots Alliance, Inc. | 68.85 Billion USD | 98.278% |
| IQVIA Holdings Inc. | 20.56 Billion USD | 94.236% |
| Heron Therapeutics, Inc. | 256.47 Million USD | -362.26% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 83.318% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -3079.234% |
| Waters Corporation | 3.47 Billion USD | 65.897% |
| Biogen Inc. | 12.04 Billion USD | 90.157% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -1338.259% |
| Evolus, Inc. | 209.68 Million USD | -465.414% |
| Adicet Bio, Inc. | 37.12 Million USD | -3093.966% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -1624.283% |
| bluebird bio, Inc. | 424.62 Million USD | -179.212% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | -79.422% |
| FibroGen, Inc. | 585.72 Million USD | -102.415% |
| Agilent Technologies, Inc. | 4.91 Billion USD | 75.893% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -3270.373% |
| Homology Medicines, Inc. | 118.53 Million USD | -900.228% |
| Geron Corporation | 146.12 Million USD | -711.349% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 70.73% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | -91.936% |
| Myriad Genetics, Inc. | 312.9 Million USD | -278.907% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -5807.03% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | -372.712% |
| Zoetis Inc. | 9.29 Billion USD | 87.245% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -2310.932% |
| Mettler-Toledo International Inc. | 3.5 Billion USD | 66.179% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 37.272% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 76.978% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -2347.311% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 54.459% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | -347.844% |
| Verastem, Inc. | 71.18 Million USD | -1565.519% |
| Nektar Therapeutics | 267.04 Million USD | -343.968% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | -198.445% |
| Aclaris Therapeutics, Inc. | 40.22 Million USD | -2847.347% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 50.708% |
| OPKO Health, Inc. | 622.47 Million USD | -90.464% |
| Exelixis, Inc. | 678.44 Million USD | -74.753% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | -16.304% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -932.645% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -9359.071% |
| uniQure N.V. | 624.01 Million USD | -89.994% |
| Imunon, Inc. | 8.53 Million USD | -13798.484% |
| Blueprint Medicines Corporation | 918.64 Million USD | -29.06% |
| Insmed Incorporated | 1.66 Billion USD | 28.654% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 28.122% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -840.214% |
| TG Therapeutics, Inc. | 169.08 Million USD | -601.186% |
| Incyte Corporation | 1.59 Billion USD | 25.54% |